The Cooper Companies
COO
$61.88
-1.23%
The Cooper Companies is a global medical device company operating two segments: CooperVision, a pure-play contact lens business with a portfolio spanning spherical, toric, multifocal, and specialty lenses under brands such as Biofinity, MyDay, Clariti, and Proclear, and CooperSurgical, which supplies fertility, reproductive, and women's health equipment including the Paragard hormone-free IUD. CooperVision controls roughly one quarter of the US contact lens market, making Cooper one of the three dominant eyecare players globally alongside Alcon and Johnson & Johnson Vision, while CooperSurgical holds the broadest device coverage across the IVF cycle and about 17% of the US IUD market. The current investor narrative is dominated by a sharp credibility reset: the September 10 fiscal Q3 print beat on EPS but missed on revenue due to US inventory destocking, and the stock fell roughly 16% after hours, triggering a wave of analyst downgrades to Neutral and a collapse in the share price toward multi-year lows. The debate now centers on whether the destocking is a transient channel event or a signal of softening contact lens demand, and whether CooperSurgical's margin recovery and the company's defensive, non-discretionary eyecare franchise can re-anchor the equity as a value recovery story.…
COO
The Cooper Companies
$61.88
Related headlines
Investment Opinion: Should I buy COO Today?
Rating: Hold, with a constructive bias toward accumulating on weakness. The core thesis is that Cooper's 13.35x forward PE already discounts a full destocking-driven earnings reset, while the non-discretionary eyecare franchise, 0.338 debt-to-equity, and $678 million trailing free cash flow cap the downside — but a 5 Buy / 12 Hold / 0 Sell consensus, a 2.53 recommendation mean, and a $65.80 average target implying only +5.0% upside mean there is no catalyst yet to justify chasing the stock at $62.65.
The supporting evidence is valuation-led rather than momentum-led. Forward PE of 13.35x against trailing PE of 37.19x implies the market expects EPS to roughly triple to the $6.12 consensus, and PS of 3.42x and PB of 1.70x sit at the bottom of a three-year band that once reached 20.7x and 2.60x respectively. Free cash flow of $678 million comfortably funds $68.7 million of quarterly capex and $249.5 million of Q3 buybacks, and the current ratio of 1.89 with debt-to-equity of 0.338 leaves no refinancing overhang. The offset is that revenue grew just 0.56% YoY in Q3 2026 and gross margin fell to 62.36% from 67.99% in Q2, so the earnings recovery embedded in the forward multiple is not yet visible in reported results.
The biggest risks that could invalidate the thesis are a second consecutive revenue miss confirming structural demand weakness, gross margin failing to recover from 62.36% toward the 65-68% historical band, and the $6.12 forward EPS being cut, which would make the 13.35x multiple illusory. This Hold would upgrade to Buy on evidence of CooperVision volume reacceleration and gross margin back above 65% with the stock still below $70, and would downgrade to Sell on a break below the $51.01 52-week low or a cut to forward EPS guidance. Net verdict: the stock is modestly undervalued relative to its own history and fairly valued versus peers, but not yet cheap enough to compensate for unresolved earnings visibility.
Sign up to view all
COO 12-Month Price Forecast
The setup is a classic post-capitulation value debate: valuation at the bottom of a three-year band (PS 3.42x versus 20.7x in Q4 2024, PB 1.70x versus 2.60x) against a fundamental picture that has not yet stabilized, with revenue growth of 0.56% YoY and gross margin at 62.36%. The 14.16% one-month bounce versus SPY's -2.26% shows buyers defending the $53-55 zone, but the stock remains 22.76% down YTD with a -33.38% relative strength gap to SPY, so the trend is not yet repaired. Analyst dispersion is unusually tight on fundamentals — revenue estimates of $5.128-5.248 billion and EPS of $6.015-6.200 — meaning the disagreement is about multiple and timing, which typically resolves directionally on the next print. I would upgrade to bullish on a fiscal Q4 beat with CooperVision volume reacceleration and gross margin above 65%, and downgrade to bearish on a second revenue miss or a break below the $51.01 52-week low. Until then, the risk/reward is balanced rather than compelling, with roughly +5% to the average target against -18.6% to the 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cooper Companies's 12-month outlook, with a consensus price target around $65.80 and implied upside of +6.3% versus the current price.
Average Target
$65.80
17 analysts
Implied Upside
+6.3%
vs. current price
Analyst Count
17
covering this stock
Price Range
$58 - $75
Analyst target range
Coverage is broad with 15 analysts, but sentiment has turned decisively cautious: the distribution is 5 Buy, 12 Hold, and 0 Sell, yielding a consensus recommendation of "hold" and a recommendation mean of 2.53 (where 1 is Strong Buy and 5 is Strong Sell). The average target price is $65.80, which implies roughly +5.0% upside from the current $62.65, a modest spread that signals limited conviction rather than a strong bullish call. The consensus leans neutral-to-bearish in practice — a 12-to-5 Hold-to-Buy ratio with zero Sells is the classic post-downgrade configuration where analysts have capitulated on their ratings but not yet turned outright negative, and the September 10 downgrade wave (B of A from Buy to Neutral, Piper Sandler from Overweight to Neutral, William Blair from Outperform to Market Perform) confirms the sentiment shift is recent and broad-based. The target range of $58.00 to $75.00 is relatively tight — a spread of about 29% around the average — which signals moderate conviction rather than extreme uncertainty, and notably the low target of $58.00 sits only about 7.4% below the current price, implying even the bears see limited downside from here. The high target of $75.00 (about +19.7% upside) likely assumes destocking proves transient, CooperVision volumes reaccelerate, gross margins recover toward the 65-68% historical range, and the forward EPS of $6.12 is achieved, supporting a re-rating toward the mid-teens forward multiple. The low target of $58.00 likely prices in a slower recovery, continued margin compression from mix and under-absorption, and a prolonged destocking drag that keeps earnings near current depressed levels. The estimated revenue average of $5.196 billion (range $5.128-5.248 billion) and estimated EPS average of $6.12 (range $6.015-6.200) show tight fundamental dispersion among analysts, meaning the disagreement is about multiple and timing rather than the underlying earnings power — a configuration that typically resolves with a directional move once the next earnings print clarifies the destocking trajectory.
Bulls vs Bears: COO Investment Factors
The bear evidence currently has the stronger near-term grip: revenue growth of 0.56% YoY, gross margin down roughly 550 basis points sequentially to 62.36%, and a 12-of-15 Hold analyst consensus with only +5.0% implied upside all argue the September credibility reset is not yet resolved. The bull case rests on valuation and balance sheet rather than momentum — a 13.35x forward PE, 1.70x PB near multi-year lows, $678 million of free cash flow, and a 14.16% one-month bounce that has recovered the entire earnings gap. The single most important tension is whether US inventory destocking is a transient channel event or the leading edge of structural contact lens demand softening; if the next print shows CooperVision volumes reaccelerating and gross margin recovering toward 65%, the forward multiple re-rates and the value case wins, but a second consecutive revenue miss would validate the bears and likely retest the $51-54 zone.
Bullish
- Forward PE of 13.35x prices deep pessimism: The stock trades at 37.19x trailing PE but only 13.35x forward earnings on consensus EPS of $6.12, a 64% compression that implies the market has already discounted a full earnings recovery. Even the analyst low target of $58.00 sits just 7.4% below the $62.65 price, meaning the bear case is largely in the tape.
- Valuation at bottom of own historical band: PS has collapsed from 20.7x in Q4 2024 to 3.42x today and PB has fallen from 2.60x to 1.70x, placing Cooper near the low end of its three-year range on every book- and sales-based measure. The 15.81x EV/EBITDA is moderate for a medical device franchise with a non-discretionary eyecare end market.
- Balance sheet and cash flow fund the recovery: Debt-to-equity is only 0.338, the current ratio is 1.89, and trailing free cash flow of $678 million comfortably covers $68.7 million of quarterly capex and $249.5 million of Q3 buybacks. This gives Cooper the internal capacity to wait out destocking without dilution or covenant pressure.
- Oversold bounce shows buyers defending lows: The stock is up 14.16% over the past month versus SPY's -2.26%, a 16.42-point relative strength swing, and has clawed back to $62.65 from the September 10 gap down to $54.17 — above the pre-gap level of roughly $63.48. That price action suggests the $53-55 capitulation zone is being aggressively defended.
Bearish
- Revenue growth has stalled at 0.56% YoY: Fiscal Q3 2026 revenue of $1.0662 billion grew just 0.56% year-over-year and declined sequentially from $1.0815 billion in Q2, with revenue stuck in a $1.02-1.08 billion band for four straight quarters. The destocking miss raises the question of whether this is a channel event or genuine softening in contact lens demand.
- Gross margin compression from 68% to 62.4%: Gross margin fell from 67.99% in Q2 2026 and 67.88% in Q1 2026 to 62.36% in Q3 2026, with trailing gross margin at 60.67% versus the 65-68% historical range. Mix shift and under-absorption from lower volumes are eroding the profitability that justified Cooper's premium multiple.
- Earnings quality is distorted and volatile: Q3 net income of $432.8 million was inflated by a -$231 million tax benefit, while Q2 posted a net loss of -$77.9 million and a -7.20% net margin on a $47.7 million other-expense charge. ROE of 4.55% and ROA of 2.74% are well below historical mid-single to low-double-digit returns.
- Analyst capitulation with 12 of 15 at Hold: The September 10 downgrade wave (BofA, Piper Sandler, William Blair all cut to Neutral/Market Perform) left a 5 Buy / 12 Hold / 0 Sell distribution and a 2.53 recommendation mean. The $65.80 average target implies only +5.0% upside, signaling limited conviction rather than a bullish call.
COO Technical Analysis
The prevailing trend is a broken uptrend that has transitioned into a violent downtrend and partial stabilization. The stock is down 12.68% over the past year, down 22.76% year-to-date, and sits at $62.65, which is only about 29.6% of the way up its 52-week range of $51.01 to $89.83 — a positioning that signals the stock is trading in the lower third of its annual band and remains closer to capitulation lows than momentum highs. The maximum drawdown of -36.82% confirms a severe de-rating rather than a garden-variety pullback, and the 1-year relative strength of -24.95% versus SPY (+12.27%) underscores how decisively Cooper has lagged a rising market. Recent momentum, however, has turned sharply positive and diverges from the longer-term trend: the stock is up 14.16% over the past month versus a -2.26% decline for SPY, a 16.42-point relative strength swing, even as the 3-month change remains -17.75%. That divergence — a strong 1-month bounce inside a deeply negative 3-month and 1-year structure — is characteristic of an oversold mean-reversion rally following the September 10 earnings gap down from roughly $63.48 to $54.17, and the fact that the stock has clawed back to $62.65 (above the pre-gap level) suggests buyers are defending the $53-55 zone aggressively. The 6-month change of +5.10% versus SPY's +2.13% further supports the view that the intermediate base is forming, though the 0.46% single-day change and the flat previous close of $62.65 indicate momentum is pausing near resistance. Key technical levels are well defined: support sits at the 52-week low of $51.01, with a secondary shelf at the September capitulation zone around $53-54, while resistance lies at the 52-week high of $89.83 and, more immediately, at the $70-76 congestion band where the stock traded in July and August before the earnings break. A decisive reclaim of $70 would signal the downtrend is over and open a path toward the mid-$70s, whereas a breakdown below $51.01 would confirm a fresh leg lower and likely trigger another round of momentum selling. Volatility context matters for sizing: the beta of 0.818 implies the stock is roughly 18% less volatile than SPY on a systematic basis, but the -36.82% max drawdown and the 16% single-day earnings gap show that idiosyncratic event risk is far larger than beta suggests, so position sizing should be governed by event risk rather than market beta alone.
Beta
0.82
0.82x market volatility
Max Drawdown
-36.8%
Largest decline past year
52-Week Range
$51-$90
Price range past year
Annual Return
-14.2%
Cumulative gain past year
| Period | COO Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | -3.0% |
| 3m | -18.3% | -3.6% |
| 6m | +0.2% | -0.2% |
| 1y | -14.2% | +10.1% |
| ytd | -23.7% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COO Fundamental Analysis
The revenue trajectory has decelerated to a near-standstill: fiscal Q3 2026 revenue was $1.0662 billion, up just 0.56% year-over-year, a marked slowdown from the roughly $1.0815 billion in Q2 2026 and $1.0241 billion in Q1 2026, and the sequential decline reflects the US inventory destocking that drove the September revenue miss. Segment data shows CooperVision at $717.0 million and CooperSurgical at $349.2 million, meaning the contact lens franchise contributes roughly two-thirds of revenue and is the swing factor for growth, while the smaller surgical segment carries higher-margin fertility and IUD exposure. The multi-quarter trend is one of stagnation rather than collapse — revenue has hovered in the $1.02-1.08 billion range for four straight quarters — which implies the investment case now hinges on a volume recovery as destocking laps rather than on organic acceleration. Profitability is volatile and optically distorted: Q3 2026 net income was $432.8 million with a 40.59% net margin, but that figure was inflated by a -$231 million income tax benefit (a negative tax expense), while Q2 2026 posted a net loss of -$77.9 million and a -7.20% net margin driven by a $47.7 million other-expense charge and a -$31.0 million operating loss. Gross margin has been compressing, falling from 67.99% in Q2 2026 and 67.88% in Q1 2026 to 62.36% in Q3 2026, and the trailing gross margin of 60.67% and operating margin of 16.69% are below the 65-68% gross margins Cooper historically delivered, suggesting mix shift and under-absorption from lower volumes. The balance sheet is a genuine strength: debt-to-equity is only 0.338, the current ratio is 1.89, and trailing free cash flow is $678 million, which comfortably funds the $68.7 million of Q3 capex and the $249.5 million of Q3 share repurchases. ROE of 4.55% and ROA of 2.74% are depressed relative to the company's historical mid-single-digit to low-double-digit returns, confirming that the earnings base is cyclically impaired rather than structurally broken, and the $154.9 million cash balance plus modest leverage means Cooper has ample internal funding capacity without external financing dependence.
Quarterly Revenue
$1.1B
2026-07
Revenue YoY Growth
+0.6%
YoY Comparison
Gross Margin
62.4%
Latest Quarter
Free Cash Flow
$678000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COO Overvalued?
Because trailing net income is positive ($432.8 million in Q3 2026, albeit tax-benefit-inflated), the PE ratio is the primary metric, and the trailing PE of 37.19x against a forward PE of 13.35x is the single most important valuation signal in this dataset. That 64% compression from trailing to forward earnings implies the market expects EPS to roughly triple, consistent with the consensus forward EPS estimate of $6.12 versus the trailing figure of about $1.68 implied by the 37.19x multiple on a $62.65 price — a gap that reflects the tax-benefit distortion in trailing earnings and the expectation of a clean FY2027 recovery. On the secondary metrics, the PS ratio of 3.42x, EV/Sales of 3.44x, and EV/EBITDA of 15.81x are moderate for a medical device franchise, while the PB of 1.70x is near the low end of the company's historical band. Peer comparison against the medical instruments and supplies industry is complicated by the absence of a clean industry-average multiple in the provided data, but the internal evidence is telling: a 1.70x PB and 3.42x PS are well below the 2.0-2.6x PB and 13-21x PS the stock carried through 2023-2024, implying Cooper now trades at a meaningful discount to its own recent history and likely at or below sector medians on book value. The premium that remains — a 37.19x trailing PE — is largely an artifact of depressed, distorted trailing earnings rather than a genuine growth premium, and the negative PEG of -8.14 is meaningless given the negative growth denominator. Historical context is the strongest part of the valuation case: the stock's own PE band over the past three years ranged from roughly 8x to 57x, with the PS ratio collapsing from 20.7x in Q4 2024 to 3.42x today and PB falling from 2.60x to 1.70x, placing Cooper near the bottom of its own valuation range on every book- and sales-based measure. That positioning suggests the market is pricing in pessimistic expectations — destocking, margin compression, and a slower contact lens market — and leaves room for multiple re-expansion if the forward EPS of $6.12 materializes, though it also warns that the market may be correctly discounting structural deterioration rather than a temporary air pocket.
PE
37.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~57x
vs. Industry Avg
40.3x
Industry PE ~40.3x*
EV/EBITDA
15.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and earnings quality rather than solvency. Gross margin fell from 67.99% in Q2 2026 to 62.36% in Q3 2026, a roughly 560 basis point sequential compression driven by mix shift and under-absorption, while trailing gross margin of 60.67% and operating margin of 16.69% sit below the 65-68% historical band. Reported profitability is unreliable: Q3 net income of $432.8 million was inflated by a -$231 million tax benefit, and Q2 produced a -$77.9 million net loss with a -$31.0 million operating loss. Revenue concentration adds risk, with CooperVision at $717.0 million (roughly two-thirds of the $1.0662 billion total) making the contact lens franchise the single swing factor for growth, and revenue growth of just 0.56% YoY leaves no cushion if destocking extends. The offsetting strength is a debt-to-equity of 0.338, current ratio of 1.89, and $678 million trailing free cash flow, which limit balance-sheet risk even in a prolonged downturn.
Market and competitive risks are dominated by multiple compression and sentiment fragility. The stock carries a 37.19x trailing PE that is an artifact of distorted trailing earnings, but if the $6.12 forward EPS is not delivered the 13.35x forward multiple would prove illusory and the shares would de-rate further. Cooper competes against Alcon and Johnson & Johnson Vision in contact lenses and faces fertility and IUD competition in CooperSurgical, so any share loss compounds the volume problem already visible in the destocking miss. The beta of 0.818 implies roughly 18% less systematic volatility than SPY, but the -36.82% max drawdown and the 16% single-day earnings gap show idiosyncratic event risk far exceeds what beta suggests. Macro conditions add pressure: the September 10 news flow flagged oil above $100 and rising Treasury yields reigniting inflation and rate fears, an environment that favors value over growth and compresses multiples for premium medical device names.
The worst-case scenario is a second consecutive revenue miss that confirms destocking is structural demand weakness rather than a channel air pocket. In that chain of events, CooperVision volumes stay flat, gross margin fails to recover from 62.36%, the $6.12 forward EPS gets cut, and the 12 Hold-rated analysts capitulate toward Sell, driving the stock toward its 52-week low of $51.01 — roughly -18.6% from the current $62.65. A break below that level would confirm a fresh leg lower and likely trigger momentum selling toward the September capitulation zone of $53-54 and beyond, with the analyst low target of $58.00 offering little protection since it sits only 7.4% below the current price. Realistically, an investor could lose 18-25% from here in the adverse scenario, and the -36.82% historical max drawdown shows losses of that magnitude are within this stock's demonstrated range.

